Fibroblast apoptosis precedes cardiomyocyte mass reduction during left ventricular remodeling in hypertensive rats treated with amlodipine

Journal of Hypertension

Volumn 25, Issue 6, 2007, Pages 1291-1299

  Duguay, David ^a   Pesant, Stéphanie ^a   Deschepper, Christian F ^b   DeBlois, Denis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Apoptosis; Calcium channel blockers; Hypertension; Hypertrophy hyperplasia; Interstitial fibroblasts

Indexed keywords

AMLODIPINE; ATRIAL NATRIURETIC FACTOR; CASPASE 3; DNA; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL COUNT; CONTROLLED STUDY; ENZYME DEGRADATION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 34250381002     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280e126d5     Document Type: Article

References (40)

1. DerSarkissian S, Marchand EL, Duguay D, Hamet P, deBlois D. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc Res 2003; 57:775-783.
2. Liu JJ, Peng L, Bradley CJ, Zulli A, Shen J, Buxton BF. Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts. Cardiovasc Res 2000; 45:729-735.
3. Hamet P, Thorin-Trescases N, Moreau P, Dumas P, Tea BS, deBlois D, et al. Workshop: excess growth and apoptosis: is hypertension a case of accelerated aging of cardiovascular cells? Hypertension 2001; 37:760-766.
4. Hamet P, deBlois D, Dam TV, Richard L, Teiger E, Tea BS, et al. Apoptosis and vascular wall remodeling in hypertension. Can J Physiol Pharmacol 1996; 74:850-861.
5. Thorin-Trescases N, deBlois D, Hamet P. Evidence of an altered in vivo vascular cell turnover in spontaneously hypertensive rats and its modulation by long-term antihypertensive treatment. J Cardiovasc Pharmacol 2001; 38:764-774.
6. Walter SV, Hamet P. Enhanced DNA synthesis in heart and kidney of newborn spontaneously hypertensive rats. Hypertension 1986; 8:520-525.
7. Tea BS, Dam TV, Moreau P, Hamet P, deBlois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 1999; 34:229-235.
8. Izumi Y, Kim S, Zhan Y, Namba M, Yasumoto H, Iwao H. Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 2000; 36:511-516.
9. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91:1103-1113.
10. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998; 40:352-363.
11. Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, Beermann F, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001; 108:1843-1851.
12. Islim IF, Watson RD, Ihenacho HN, Ebanks M, Singh SP. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. Cardiology 2001; 96 (Suppl 1):10-18.
13. Kyselovic J, Krenek P, Wibo M, Godfraind T. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br J Pharmacol 2001; 134:1516- 1522.
14. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Lond) 2003; 104:341-347.
15. Nayler WG. The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. J Cardiovasc Pharmacol 1988; 12 (Suppl 7):S42-S44.
16. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003; 41:963-967.
17. 2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 41:544-552.
18. Sevilla MA, Voces F, Carron R, Guerrero EI, Ardanaz N, San Roman L, et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life Sci 2004; 75:881-891.
19. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
20. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Mizuno T, et al. Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. Hypertension 1998; 31:32-38.
21. Guide to the care and use of experimental animals. Ottawa: Canadian Council on Animal Care publication; 1993.
22. Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97:2891-2897.
23. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967; 18:267-273.
24. Masciotra S, Picard S, Deschepper CF. Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. Circ Res 1999; 84:1453-1458.
25. Anversa P, Zhang X, Li P, Capasso JM. Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J Clin Invest 1992; 89:618-629.
26. Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 1985; 54:589-599.
27. Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006; 24:2057-2069.
28. Bowen-Pope DF, Schaub FJ. Apoptosis of smooth muscle cells is not silent: Fas/FADD initiates a program of inflammatory gene expression. Trends Cardiovasc Med 2001; 11:42-45.
29. Diez J, Panizo A, Hernandez M, Vega F, Sola I, Fortuno MA, et al. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997; 30:1029-1034.
30. Sharifi AM, Schiffrin EL. Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am J Hypertens 1998; 11:1108-1116.
31. Rabkin SW, Kong JY. Nifedipine does not induce but rather prevents apoptosis in cardiomyocytes. Eur J Pharmacol 2000; 388:209-217.
32. Yu G, Liang X, Xie X, Su M, Zhao S. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats. Int J Cardiol 2001; 81:123-129.
33. deBlois D, Tea BS, Beaudry D, Hamet P. Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. Can J Physiol Pharmacol 2005; 83:29-41.
34. Bataller R, Gasull X, Gines P, Hellemans K, Gorbig MN, Nicolas JM, et al. In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology 2001; 33:956-962.
35. Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation 1999; 99:2523-2529.
36. Yu T, Morita I, Shimokado K, Iwai T, Yoshida M. Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction. Hypertension 2003; 42:329-334.
37. Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39:208-214.
38. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
39. Shibasaki Y, Nishiue T, Masaki H, Matsubara H, Iwasaka T. Angiotensin II type 1 antagonist suppresses left ventricular hypertrophy and myocardial fibrosis in patients with end stage renal disease (ESRD) [in Japanese]. Nippon Rinsho 2002; 60:1992-1998.
40. Gonzalez A, Lopez B, Ravassa S, Querejeta R, Larman M, Diez J, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39:75-80.